Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504209 | 0.86 | KDM4E (0.68) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| Hydrochloric Acid SCHEMBL30925271 | 0.83 | KDM4E (0.74) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| SCHEMBL17123634 | 0.79 | KDM4E (0.54) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| SCHEMBL20630777 | 0.79 | KDM4E (0.54) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| SCHEMBL13184538 | 0.78 | KDM4E (0.59) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| SCHEMBL11172866 | 0.78 | CXCR3 (0.52) | CYP3A4CYP1A2CYP2D6APPAPEX1 | |
| SCHEMBL20245275 | 0.77 | KDM4E (0.52) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| SCHEMBL2848915 | 0.76 | MAPT (0.56) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| SCHEMBL296509 | 0.76 | MAPT (0.56) | CYP3A4KDM4EMAPTLOXL2NCF1 | |
| SCHEMBL23527906 | 0.75 | CXCR3 (0.46) | CYP3A4CYP1A2CYP2D6APPAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120794861-A | Amine compound for fungus medicine and preparation method thereof | 芷威（上海）化学科技有限公司 | 2025-10-17 | — | — | CN | disclosed |
| EP-4069697-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-4169944-A1 | PROCESS FOR PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4069697-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-3904352-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021113263-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-110950812-B | Triazole compound and application thereof in agriculture | 东莞市东阳光农药研发有限公司 | 2020-11-10 | — | — | CN | disclosed |
| WO-2020207352-A1 | TRIAZINE BENZIMIDAZOLE COMPOUNDS AND MEDICAL USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-10-15 | — | — | WO | disclosed |
| US-9533965-B2 | 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-03 | — | — | US | disclosed |
| EP-2813495-B1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2813495-B1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2813495-A1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813495-A1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-12-17 | — | — | EP | disclosed |
| EP-2395002-B1 | PHARMACEUTICAL COMPOSITION CONTAINING A HETEROCYCLIC MODULATOR OF ATP-BINDING CASSETTE TRANSPORTERS. | VERTEX PHARMA (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2404919-B1 | Heterocyclic compound useful as a modulator of ATP-binding cassette transporters. | VERTEX PHARMA (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8211402-B2 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRH, CRHR2 | CYP3A4 3744/4885KDM4E 4829/4885MAPT 4580/4885 |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | CA9, CA13, CA14 | CYP3A4 4511/4885KDM4E 3438/4885MAPT 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.